The use of Goserelin in the management of endometriosis

Jagidesa Moodley, S.R. Ramphal
In: Obstetrics and Gynaecology Forum · 2009 · vol. 19(1) · doi:10.4314/ogf.v19i1.43679 · W2042355396
OA: closed CC0 ⤵ 1 in-corpus citation
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-04 ⓘ

This paper describes the Goserelin acetate implant, a synthetic GnRH agonist analogue designed for subcutaneous injection in the management of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-04 · read from full text ⓘ

This article reviews the clinical application of Goserelin, a synthetic GnRH agonist analogue formulated as a biodegradable implant for subcutaneous injection. The text outlines the pharmacological mechanism by which the drug suppresses gonadotropin secretion to manage endometriosis symptoms. It serves as a descriptive overview of the medication's role within gynecological practice rather than presenting new empirical data from a controlled trial. This paper is centrally about endometriosis — specifically the use of GnRH agonists like Goserelin in its medical management.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Zoladex (Goserelin acetate implant) contains a synthetic decapeptide analogue of luteinising hormone releasing (GnRH) agonist analogue. Zoladex is designed for subcutaneous injection (sterile biodegradable productequivalent to 3.6mg Goserelin)
Full text 508 characters · extracted from oa-doi-fallback · click to expand
Main Article Content The use of Goserelin in the management of endometriosis Abstract equivalent to 3.6mg Goserelin) Journal / Obstetrics and Gynaecology Forum / Vol. 19 No. 1 (2009) / Articles Zoladex (Goserelin acetate implant) contains a synthetic decapeptide analogue of luteinising hormone releasing (GnRH) agonist analogue. Zoladex is designed for subcutaneous injection (sterile biodegradable product equivalent to 3.6mg Goserelin) equivalent to 3.6mg Goserelin) eISSN: 1027-9148 print ISSN: 1029-1962

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-11-06T06:34:47.334260+00:00
License: CC0 · commercial use OK